Literature DB >> 18753338

Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Bruno Garulli1, Maria G Stillitano, Vincenzo Barnaba, Maria R Castrucci.   

Abstract

The efficiency of cross-presentation of exogenous antigens by dendritic cells (DCs) would seem to be related to the level of antigen escape from massive degradation mediated by lysosomal proteases in an acidic environment. Here, we demonstrate that a short course of treatment with chloroquine in mice during primary immunization with soluble antigens improved the cross-priming of naïve CD8(+) T lymphocytes in vivo. More specifically, priming of chloroquine-treated mice with soluble ovalbumin (OVA), OVA associated with alum, or OVA pulsed on DCs was more effective in inducing OVA-specific CD8(+) T lymphocytes than was priming of untreated mice. We conclude that chloroquine treatment improves the cross-presentation capacity of DCs and thus the size of effector and memory CD8(+) T cells during vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753338      PMCID: PMC2565925          DOI: 10.1128/CVI.00166-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  58 in total

1.  Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages.

Authors:  C C Norbury; L J Hewlett; A R Prescott; N Shastri; C Watts
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

Review 2.  Antigen processing and presentation by the class I major histocompatibility complex.

Authors:  I A York; K L Rock
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 3.  Capture and processing of exogenous antigens for presentation on MHC molecules.

Authors:  C Watts
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy.

Authors:  G Cambie; F Verdier; C Gaudebout; F Clavier; H Ginsburg
Journal:  Parasite       Date:  1994-09       Impact factor: 3.000

5.  Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.

Authors:  Y Ke; Y Li; J A Kapp
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

6.  Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells.

Authors:  C C Norbury; B J Chambers; A R Prescott; H G Ljunggren; C Watts
Journal:  Eur J Immunol       Date:  1997-01       Impact factor: 5.532

Review 7.  Adjuvants for human vaccines--current status, problems and future prospects.

Authors:  R K Gupta; G R Siber
Journal:  Vaccine       Date:  1995-10       Impact factor: 3.641

8.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.

Authors:  P Brossart; M J Bevan
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

9.  Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.

Authors:  S R Bennett; F R Carbone; F Karamalis; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

10.  Defective CD8 T cell memory following acute infection without CD4 T cell help.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

View more
  20 in total

1.  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Authors:  Geert Leroux-Roels; Patricia Bourguignon; Julie Willekens; Michel Janssens; Frédéric Clement; Arnaud M Didierlaurent; Laurence Fissette; François Roman; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

Review 2.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

Review 3.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

4.  Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.

Authors:  Renato B Baleeiro; René Rietscher; Andrea Diedrich; Justyna A Czaplewska; Claus-Michael Lehr; Regina Scherließ; Andrea Hanefeld; Michael Gottschaldt; Peter Walden
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

5.  IFN-{gamma} produced by CD8 T cells induces T-bet-dependent and -independent class switching in B cells in responses to alum-precipitated protein vaccine.

Authors:  Elodie Mohr; Adam F Cunningham; Kai-Michael Toellner; Saeeda Bobat; Ruth E Coughlan; Roger A Bird; Ian C M MacLennan; Karine Serre
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

6.  HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.

Authors:  Leonia Bozzacco; Christine Trumpfheller; Yaoxing Huang; Maria Paula Longhi; Irina Shimeliovich; Joseph D Schauer; Chae Gyu Park; Ralph M Steinman
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

7.  In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.

Authors:  Fadel S Alyaqoub; Yasser A Aldhamen; Benjamin J Koestler; Eric L Bruger; Sergey S Seregin; Cristiane Pereira-Hicks; Sarah Godbehere; Christopher M Waters; Andrea Amalfitano
Journal:  J Immunol       Date:  2016-01-20       Impact factor: 5.422

8.  IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo.

Authors:  Karine Serre; Elodie Mohr; Fabrina Gaspal; Peter J L Lane; Roger Bird; Adam F Cunningham; Ian C M Maclennan
Journal:  Mol Immunol       Date:  2010-04-13       Impact factor: 4.407

9.  Improved antigen cross-presentation by polyethyleneimine-based nanoparticles.

Authors:  Jian Chen; Zhengrong Li; Hong Huang; Yanzhu Yang; Qian Ding; Junhua Mai; Wei Guo; Yuhong Xu
Journal:  Int J Nanomedicine       Date:  2011-01-06

10.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.